Abstract
The constant release of human bone morphogenetic protein 2 (rhBMP-2) in the picomolar range (Pico-Stat) from PDLLA-biohybrids led to the detection of intrinsic novel pro- and anti-angiogenic functions of this cytokine. As integrant part in this perspective of previous work, first evidence for the binding of rhBMP-2, as an inverse agonist, to allosteric angiogenic receptors in cocultures of human endothelial cells is reported.
Subject
Biomedical Engineering,Histology,Bioengineering,Biotechnology
Reference27 articles.
1. Electrospun PDLLA nanofiber fleece loaded with low concentrated rhBMP-2 enhances bone regeneration by activating both angiogenesis and osteogenesis in vivo;Al-Maawi;Manuscript in preparation,2023
2. Making sense of pharmacology: inverse agonism and functional selectivity;Berg;Int. J. Neuropsychopharmacol.,2018
3. Biocoating of electropolished and ultra-hydrophilic titanium and cobalt chromium molybdenium alloy surfaces with proteins;Chatzinikolaidou;Mater. Werkst. Mat. Sci. Eng. Technol. ),2002
4. InductOs-EMEA/H/C/000408-II/0100 EMA/CHMP/649027/2014,2014
5. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A;Deckers;Endocrinology,2002